



**ESOU19**

16th Meeting of the EAU Section of  
Oncological Urology

18-20 January 2019, Prague, Czech Republic

[www.esou19.org](http://www.esou19.org)

**esou**

**EAU**  
European  
Association  
of Urology

## Scientific Programme

### Friday, 18 January

**08.30 – 08.40 Welcome**

M. Brausi, Modena (IT)

M. Babjuk, Prague (CZ)

**08.40 – 08.55 Opening address**

**History and impact of ESOU in onco-urology**

M. Brausi, Modena (IT)

**08.55 – 10.15 Prostate cancer I: Prevention, diagnosis and active surveillance**

Chairs : M Brausi, Modena (IT)

M. Wirth, Dresden (DE)

**08.55 – 09.10 Prostate cancer prevention: An update**

S. Brookman-May, Munich (DE)

**09.10 – 09.25 Why genetic tests are not there yet**

J. Moul, Durham (US)

**09.25 – 09.50 Debate: mp-MRI should be used routinely in patients with an elevated PSA (short introductory case how to digest the PRECISION study-introduced by chair)**

**09.25 – 09.35 YES always**

C. Moore, London (GB)

**09.35 – 09.45 NO only in selected cases**

N. Mottet, Saint Etienne (FR)

**09.45 – 09.50 Discussion**

**09.50 – 10.10 Definition and interpretation of PI-RADS 3 on mp-MRI: Counselling patients**

J. Barentsz , Nijmegen (NL) Radiologist

J. Radtke, Heidelberg (DE) Urologist

**10.10 – 10.15 Discussion**

**10.15 – 13.00 Prostate cancer II**

Chairs: B. Djavan, Vienna (AT)

N. Mottet, Saint Etienne (FR)

**10.15 – 10.30 Risk stratification for active surveillance**

N. Mottet, Saint Etienne (FR)

**10.30 – 10.35 Discussion**

**10.35 – 10.50 The role of mpMR in active surveillance : Case presentation and discussion**

A. Masson-Lecomte, Paris (FR)

J. Barentsz, Nijmegen (NL)

**10.50 – 11.20 Break**

**11.20 – 12.10 Treatment of GS 7 (3+4) in an MDT scenario : Case presentation and debate**

**11.20 – 11.30 Active surveillance**

M. Roobol, Rotterdam (NL)

**11.30 – 11.40 Focal therapy**

C. Orczyk, London (GB)

**11.40 – 11.50 Surgery**

H. Van der Poel, Amsterdam (NL)

**11.50 – 12.00 Hypofractionation RT**

A. Bossi, Villejuif (FR)

**12.00 – 12.10 Discussion**

**12.10 – 13.00 What is high quality local treatment in high risk localised prostate cancer?**

**12.10 – 12.30 Surgery**

S. Joniau, Leuven (BE)

**12.30 – 12.50 Radiotherapy**

P. Nguyen, Boston (US)

**12.50 – 13.00 Discussion**

**13.00 – 13.45 Lunch**

**13.45 – 16.10 Renal cancer I: Localised: Diagnosis**

Chairs: H. Van Poppel, Leuven (BE)

A. Volpe, Novara (IT)

**13.45 – 14.05 Diagnosis and treatment of cystic renal masses**

**13.45 – 13.55 Classification and role of cross-sectional imaging (CT/MRI)**

T.b.c.

**13.55 – 14.05 Role of contrast enhanced ultrasound**

J. Rübenthaler, Munich (DE)

**14.05 – 14.40 Case presentation and debate**

**Cystic renal tumors: What is the best surgical approach for partial nephrectomy?**

Chair: A. Volpe, Novara (IT)

**14.05 - 14.15 Open (video)**

H. Van Poppel, Leuven (BE)

- 14.15 - 14.25 **Laparoscopy (video)**  
T.b.c.
- 14.25 - 14.35 **Robotic (video)**  
R. Nair, London (GB).
- 14.35 – 14.40 **Discussion**
- 14.40 - 15.10 Debate**  
**T2 renal tumors: what is the best surgical treatment?**
- 14.40 – 14.50 **Radical nephrectomy**  
P. Mulders, Nijmegen (NL)
- 14.50 - 15.00 **Partial nephrectomy**  
K. Bensalah, Rennes (FR)
- 15.00 - 15.10 **Discussion**
- 15.10 – 15.40 Panel discussion of clinical cases: Localized RCC**  
Moderators: A. Alcaraz, Barcelona (ES)  
M. Sedelaar, Nijmegen (NL)
- Panel:  
R. Nair, London (GB)  
K. Bensalah, Rennes (FR)  
A. Mottrie, Aalst (BE)
- 15.40 - 16.10 Intraperitoneal vs extraperitoneal robotics/lap partial nephrectomy (Videos)**
- 15.40 – 15.50 **Intraperitoneal PN - when and how?**  
A. Mottrie, Aalst (BE)
- 15.50 – 16.00 **The extraperitoneal approach – when and how?**  
F. Porpiglia, Turin (IT)
- 16.00 – 16.10 **Discussion**
- 16.10 – 16.30 Break**
- 16.30 - 18.00 Urothelial and bladder cancer I: Diagnosis and staging**  
Chairs: M. Colombel, Lyon (FR)  
G. Thalmann, Berne (CH)
- 16.30 – 16.40 MRI for bladder cancer staging**  
V. Panebianco, Rome (IT)
- 16.40 – 16.50 Is en-bloc TUR the best staging tool?**  
B. Malavaud, Toulouse (FR)

**16.50 – 17.00 Confocal laser endomicroscopy (Cellvizio) for the diagnosis of Cis and Dysplasia**

M. Brausi, Modena (IT)

**17.00 – 17.10 Discussion**

**17.10 – 17.20 Epigenetics in NMIBC**

J.A. Witjes, Nijmegen (NL)

**17.20 – 17.30 Discussion**

**17.30 – 18.00 Clinical case presentation on NMIBC**

Moderators: M. Babjuk, Prague (CZ)

J. Palou, Barcelona (ES)

Panel:

A. Brisuda, Prague (CZ)

M. Colombel, Lyon (FR)

B. Malavaud, Toulouse (FR)

J. Witjes, Nijmegen (NL)

A. Xylinas, Paris (FR)

# Saturday, 19 January

## **08.00 – 10.10 Prostate Cancer III: Locally advanced disease**

Chairs: A. Heidenreich, Cologne (DE)

S. Joniau, Leuven (BE)

## **08.00 – 08.15 Reliability of PET CT in primary staging**

A. Briganti, Milan (IT)

## **08.15 – 08.20 Discussion**

## **08.20 – 09.05 Treatment of positive pelvic lymph nodes: clinical case in MDT**

### **08.20 – 08.30 Surgery**

A. Briganti, Milan (IT)

### **08.30 – 08.40 Radio hormonal therapy**

T. Wiegel, Ulm (DE)

### **08.40 – 08.50 Systemic treatments**

M. De Santis, Berlin (DE)

### **08.50 - 09.00 Genomics**

G. Kristiansen, Bonn (DE)

### **09.00 – 09.05 Discussion**

## **09.05 – 09.40 How to deal with nightmare complications of surgery and radiotherapy**

### **09.05 – 09.15 Fistulae**

G. Bislenghi, Leuven (BE)

### **09.15 – 09.25 Radiation cystitis**

M. Colombel, Lyon (FR)

### **09.25 – 09.35 Recurrent strictures**

R. Djjinovic, Belgrade (RS)

### **09.35 – 09.40 Discussion**

## **09.40 - 10.10 Case discussion: Predictors of local regional recurrence**

Chair : J. Moul, Durham (US)

### **Panel**

N. Fossati, Milan (IT)

S. Joniau, Leuven (BE)

D. Pfister, Cologne (DE)

### **10.00 – 10.10 Discussion**

## **10.10 – 10.30 Break**

- 10.30 – 12.10 Penile and testis cancer**  
Chairs: S. Minhas, London (GB)  
N. Nicolai, Milan (IT)
- 10.30 – 10.40 Minimally invasive inguinal lymphadenectomy**  
J. Gaya Sopena, Barcelona (ES)
- 10.40 – 11.00 MDT case discussion: Multi modal treatment bulky disease**  
Panel: G. de Meerleer, Ghent (BE)  
M. de Santis, Berlin (DE)  
N. Nicolai, Milan (IT)
- 11.00 – 11.15 Molecular markers for staging and monitoring testis cancer**  
A. Radtke, Bremen (DE)
- 11.15 – 11.25 Discussion**
- 11.25 – 11.55 The role of RPLND in tumour marker negative stage 2 A–B: Pro/con**  
**Pro:** P. Albers, Dusseldorf (DE)  
**Con:** T. Tandstad, Trondheim (NO)
- 11.55 – 12.10 Challenging the dogma in surgical treatment of testis cancer**  
A. Heidenreich, Cologne (DE)
- 12.10 – 13.00 Lunch**
- 13.00 – 15.30 Urothelial cancer II**  
Chairs: M. Babjuk, Prague (CZ)  
J. Palou, Barcelona (ES)
- 13.00 – 13.15 Genetics in urothelial cancer**  
S. Lerner, Houston (US)
- 13.15 – 14.00 Panel discussion: Challenging case : Low volume MIB**  
Panel:  
J. Bellmunt, Barcelona (ES)  
G. Thalmann, Berne (CH)  
P. Nguyen, Boston (US)  
S. Lerner, Houston (US)
- 14.00 – 14.35 Optimising functional outcomes in radical cystectomy**
- 14.00 – 14.10 Prostate sparing approaches**  
R. Sanchez-Salas, Paris (FR)
- 14.10 – 14.20 Robotic nerve sparing RC**  
J. Palou, Barcelona (ES)
- 14.20 – 14.30 Open nerve sparing RC**  
A. Stenzl Tubingen (DE)
- 14.30 – 14.35 Discussion**

- 14.35 - 14.45 Conservative management of upper tract urinary cancer**  
A. Breda, Barcelona (ES)
- 14.45 – 14.50 Discussion**
- 14.50 – 15.05 POUT Trial – Final result**  
R. Jones, Glasgow (GB)
- 15.05 – 15.10 Discussion**
- 15.10 – 15.25 New perspectives in UUT TCC Treatment**  
M. Roupret, Paris (FR)
- 15.25 – 15.30 Discussion**
- 15.30 – 15.40 Break**
- 15.40 – 18.30 ESU Course on the treatment of localised and locally advanced prostate cancer**  
Chair: S. Joniau, Leuven (BE)
- Faculty:** A. Heidenreich, Cologne (DE)  
G. De Meerleer, Ghent (BE)

### **Aims and objectives**

This course addresses the urological management of localized and locally advanced prostate cancer in all relevant aspects. The aim is to provide practical tips and tricks, taking into account the most recent developments in the field. Also, the management of recurrent disease will be reviewed and new developments in multimodal treatment will be critically assessed for their ability to improve cancer control.

- 15.40 – 15.45 European School of Urology: a unique possibility for urological education**  
S. Joniau, Leuven (BE)
- 15.45 – 15.50 Introduction and aims**  
S. Joniau, Leuven (BE)
- 15.50 – 16.10 Diagnosis, biopsy and staging of prostate cancer**  
S. Joniau, Leuven (BE)
- 16.10 – 16.25 Planning the surgical procedure and estimating surgical risk**  
A. Heidenreich, Cologne (DE)
- 16.25 – 16.40 Open nerve-sparing radical prostatectomy for localized PCa (video)**  
A. Heidenreich, Cologne (DE)
- 16.40 – 16.55 Pelvic lymphadenectomy in the primary and salvage setting (video)**  
S. Joniau, Leuven (BE)
- 16.55 – 17.15 Modern radiotherapy for localised and locally advanced prostate cancer (video)**  
G. de Meerleer, Leuven (BE)
- 17.15 – 17.25 Active surveillance**  
S. Joniau, Leuven (BE)
- 17.25 - 17.40 Break**

**17.40 – 18.00 Treatment of biochemical recurrence post-radiotherapy: Salvage radical prostatectomy/salvage vesiculectomy (video)**

A. Heidenreich, Cologne (DE)

**18.00 – 18.20 Treatment of biochemical recurrence post-surgery: Role of PET imaging/Adjuvant and Salvage RT**

G. De Meerleer, Ghent (BE)

**18.20 – 18.30 Discussion and close**

-o-o-o-o-o-o-

**16.00 – 18.00 STEPS (Session To Evaluate Progress) programme  
Closed programme: participation by invitation only**

Led by Prof. M. Brausi, Modena (IT)

Prostate Cancer table: Chair: J Moul, Durham (US)

ESOU: M. Brausi, Modena (IT)

Bladder Cancer table: Chair: S. Lerner, Houston (US)

ESOU: X. Xylinas, Paris (FR)

Renal Cancer table: Chair: P. Mulders, Nijmegen (NL)

ESOU: A. Volpe, Novara (IT)

Testis Cancer table: Chair: D. Pfister, Cologne (DE)

ESOU: M. Sedelaar, Nijmegen (NL)

**09.00 – 12.30 ESU Hands-on training course in prostate MRI reading for urologists**



# Sunday, 20 January

## **08.30 – 10.00 Renal cancer II: Locally advanced and metastatic**

Chairs: A. Bex, Amsterdam (NL)  
O. Rodriguez Faba, Barcelona (ES)

## **08.30 - 09.30 Adjuvant therapy after nephrectomy for high risk RCC: should we recommend it?**

### **08.30 - 08.40 The urologist's perspective**

A. Bex, Amsterdam (NL)

### **08.40 – 08.50 The oncologist's perspective**

A. Bamias, Athens (GR)

## **08.50 – 09.05 Cytoreductive nephrectomy: What are the current recommendations?**

A. Mejean, Paris (FR)

## **09.05 – 09.20 Revolution in first line treatment for mRCC: Where do we stand?**

P. Mulders, Nijmegen (NL)

## **09.20 - 09.30 Discussion**

## **09.30 – 10.00 Panel discussion of clinical cases: Advanced and metastatic RCC**

Case presenter: O. Rodriguez Faba, Barcelona (ES)

Panel:

A. Bex, Amsterdam (NL)  
P. Mulders, Nijmegen (NL)  
M. Staehler, Munich (DE)

## **10.00 - 10.30 Break**

## **10.30 - 11.30 Best of uro-oncology 2018**

Chair: A. Breda, Barcelona (ES)

### **10.30 - 10.45 Prostate cancer**

M. Sedelaar, Nijmegen (NL)

### **10.45 - 11.00 Urothelial cancer**

M. Stanik, Brno (CZ)

### **11.00 - 11.15 Renal cancer**

B. Akdogan, Ankara (TR)

### **11.15 - 11.30 Testis and penile cancer**

B. Ayres, London (GB)

## **11.30 - 13.00 Prostate cancer IV: Advanced and metastatic disease**

Chairs: A. Heidenreich, Cologne (DE)  
N. Mottet, Saint Etienne (FR)

- 11.30 – 11.45 Oligo metastatic disease today - Diagnostic and treatment**  
J. Moul, Durham (US)
- 11.45 – 12.30 Case presentation : How do I treat primary metastatic disease?**
- 11.45 – 11.55 Systemic therapy alone**  
J. Bellmunt, Barcelona (ES)
- 11.55 – 12.05 Surgery plus or minus radiotherapy**  
A. Heidenreich, Cologne (DE)
- 12.05 – 12.30 Clinical case discussion**  
J. Bellmunt, Barcelona (ES)  
A. Heidenreich, Cologne (DE)
- 12.30 - 12.45 How do I treat CRPC ?**  
A. Alcaraz, Barcelona (ES)
- 12.45 – 12.50 Discussion**
- 12.50 – 13.00 Closing remarks**  
M. Brausi, Modena (IT)